Celldex Therapeutics, Inc. (NASDAQ:CLDX) represented a move of -1.29 percent or $0.01 per share and closed its previous day trading session at $2.29. 1.34 Million Shares were traded in the last trading session with an Average Volume of 1.14 Million Shares. The stock currently has a Market Capitalization of 320.6 Million.
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex’s immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
The stock traded between $2.20 and $3.94 over 1-Year time period showing its price to sales ratio of 28.62. Celldex Therapeutics, Inc. (NASDAQ:CLDX) is currently showing an INCREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-18.62 and 200-Day Simple Moving Average of $-15.61. Its Price to Free Cash Flow is 0 and Price to Book of 1.36.
Analyst’s recommended the stock as 2.3 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported its Actual EPS of $-0.2/share. The analysts offering Earnings Estimates for the company were believing that Celldex Therapeutics, Inc. could bring EPS of $-0.27/share. The difference between Actual EPS and Estimated EPS was 0.07 Percent. Thus showing an Earnings Surprise of 25.9 Percent.
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV)
In the last trading session, ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) added its value by -1.33% closing at the price of $0.26. The stock currently has market capitalization of 19.69 Million, with average volume of 968.62 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) is showing beta of 1.3. This particular value of beta suggests that ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) has historically moved 130% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) is at $-0.24.
The stock currently has RSI of 40.73. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
ContraVir Pharmaceuticals Inc. is a biopharmaceutical company. The company is involved in the discovery and development of antiviral therapies. ContraVir Pharmaceuticals Inc. is headquartered in Edison, New Jersey.
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) topped its 52-week high price of $1.960 on 04/04/17 and 52-Week Low Price of $0.230 on 02/06/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 13.53% and monthly volatility of 10.56% respectively.